MEDINDIA
English
हिन्दी
Español
français
中文
"With the launch of deCODE MI, we have taken another of our breakthroughsin genetics and transformed it into a new tool in the fight to prevent heartattack. While many risk factors for heart attack are understood, the diseaseremains the leading cause of death in the industrialized world and the early-onset cases often take both patients and doctors so dangerously by surprise.deCODE MI(TM) tests for a genetic risk factor that is independent of otherrisks such as cholesterol, obesity and smoking, and therefore provides a meansof identifying individuals who may derive particular benefit from earlier andmore aggressive prevention efforts," said Dr. Kari Stefansson, CEO of deCODE.
How to order deCODE MI(TM)
deCODE MI(TM) is performed in deCODE's Clinical Laboratory ImprovementAmendments (CLIA) certified laboratory, and must be authorized by a qualifiedphysician. If you are an individual who would like more information on deCODEMI(TM) to discuss with your doctor, or a physician interested in learning moreabout deCODE MI(TM) for your patients, please visit us atwww.decodediagnostics.com.
The variants detected by deCODE MI(TM), are two SNPs (single-lettervariants in the genome) on chromosome 9p21. They were discovered by deCODEscientists earlier this year through genome-wide SNP analysis in Iceland andreplicated in three cohorts of European descent from Philadelphia, Atlanta andDurham, North Carolina. Of the 17,000 patients and control subjects in thestudy, more than 20% of participants carried two copies of the variant,corresponding to a more than 60% increase in risk of heart attack, regardlessof age of onset, compared to those without the variant. In early-onset cases-- men and women who suffered a heart attack before the ages of 50 and 60,respectively -- carrying two copies of the variant corresponds to anapproximate doubling of risk compared to non-carriers. The variant isestimated to account for approximately one-fifth of the incidence of heartattack in populations of European origin, and nearly one third of early-onsetcases, making it the one of the most significant genetic risk factors found todate for heart attack as a public health problem.
About deCODE
deCODE is a biopharmaceutical company applying its discoveries in humangenetics to the development of drugs and diagnostics for common diseases.deCODE is a global leader in gene discovery -- our population approach andresources have enabled us to isolate key genes contributing to major publichealth challenges from cardiovascular disease to cancer, genes that areproviding us with drug targets rooted in the basic biology of disease. Throughits CLIA-certified laboratory, deCODE is offering a growing range of DNA-basedtests for gauging risk and empowering prevention of common diseases, includingdeCODE T2(TM) in type 2 diabetes; deCODE AF(TM) for atrial fibrillation andstroke; and deCODE MI(TM) for heart attack. deCODE is delivering on thepromise of the new genetics(SM). On the web at www.decode.com.
Any statements contained in this presentation that
